Furthermore, according to the multivariate analysis result, the expression of lncRNA-AL390243.1 (OR 5.143; 95% CI: 1.570-16.847, p=0.007), tumor type (OR 0.144; 95% CI: 0.024-0.855, p=0.033), and nodal stage (OR 0.507; 95% CI: 0.289-0.888, p=0.018) were indicated as independent predictors for apCR after NAT in HER2+ patients (Table 4). The gene discussed is ERBB2; the disease is neoplasm.